Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Leo Innovation Lab

- PMLiVE

LEO shares positive results for delgocitinib cream in head-to-head chronic hand eczema study

Hand eczema is the most common skin disorder of the hands and one of the most common eczemas

- PMLiVE

LEO Pharma’s delgocitinib cream shows promise in long-term chronic hand eczema study

There are currently no topical treatments specifically approved for moderate-to-severe CHE

- PMLiVE

LEO Pharma to acquire Timber Pharmaceuticals in deal worth up to $36m

The transaction gives LEO access to Timber’s lead investigational candidate, TMB-001

- PMLiVE

LEO Pharma enters clinical trial partnership with ICON

The collaboration will focus on advancing clinical trial execution within medical dermatology

- PMLiVE

LEO Pharma reports positive results for chronic hand eczema topical treatment

Hand eczema is the most common skin disorder of the hands and one of the most common types of eczema

- PMLiVE

LEO Pharma’s delgocitinib cream shows promise in phase 3 chronic hand eczema study

There are no topical treatments specifically developed and approved for moderate-to-severe CHE

- PMLiVE

MHRA approves LEO Pharma’s Adtralza for adolescent patients with atopic dermatitis

The changes to the terms were also approved by the EC in October

- PMLiVE

NICE issues final appraisal recommending LEO Pharma’s Adtralza for moderate-to-severe atopic dermatitis

The recommendation will give those living with the condition in England and Wales access to a new treatment option

- PMLiVE

Key emerging trends in digital health

Improving healthcare for patients and helping doctors be more efficient

- PMLiVE

Current and future trends for developing digital medical communications

Evolving digital trends and user needs

- PMLiVE

BMS partners with Voluntis to co-develop oncology digital therapeutics

Aims to create a mobile app to help patients self-manage their symptoms

Digital divergence

Combining digital and pharma is proving less easy than previously thought

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links